Emil D. Kakkis - Dec 30, 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Dec 30, 2022
Transactions value $
-$892,352
Form type
4
Date filed
1/3/2023, 03:45 PM
Previous filing
Mar 3, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$892K -19.6K -3.49% $45.57 541K Dec 30, 2022 Direct F1, F2, F3
holding RARE Common Stock 2.28M Dec 30, 2022 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200 F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.94 to $46.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F4 Reflects transfer of directly owned shares of common stock from the Reporting Person to a trust indirectly held by the Reporting Person that have taken place since the most recent prior report on Form 4.